KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Operating Expenses: 2012-2024

Historic Operating Expenses for Xenon Pharmaceuticals (XENE) over the last 13 years, with Dec 2024 value amounting to $279.3 million.

  • Xenon Pharmaceuticals' Operating Expenses rose 30.76% to $96.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $348.3 million, marking a year-over-year increase of 36.30%. This contributed to the annual value of $279.3 million for FY2024, which is 30.48% up from last year.
  • Xenon Pharmaceuticals' Operating Expenses amounted to $279.3 million in FY2024, which was up 30.48% from $214.1 million recorded in FY2023.
  • In the past 5 years, Xenon Pharmaceuticals' Operating Expenses ranged from a high of $279.3 million in FY2024 and a low of $63.5 million during FY2020.
  • Its 3-year average for Operating Expenses is $210.6 million, with a median of $214.1 million in 2023.
  • Data for Xenon Pharmaceuticals' Operating Expenses shows a peak YoY surged of 54.47% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Xenon Pharmaceuticals' Operating Expenses stood at $63.5 million in 2020, then skyrocketed by 53.51% to $97.4 million in 2021, then skyrocketed by 42.23% to $138.6 million in 2022, then skyrocketed by 54.47% to $214.1 million in 2023, then surged by 30.48% to $279.3 million in 2024.